Urinary CD4+ T cells Predict Renal Relapse in ANCA-Associated Vasculitis: Results of the PRE-FLARED Study.


Journal

Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836

Informations de publication

Date de publication:
17 Jan 2024
Historique:
received: 21 07 2023
accepted: 04 01 2024
medline: 17 1 2024
pubmed: 17 1 2024
entrez: 17 1 2024
Statut: aheadofprint

Résumé

In ANCA-associated vasculitis (AAV) there is a lack of biomarkers for predicting renal relapse. Urinary T cells have been shown to differentiate active glomerulonephritis from remission in AAV, but their predictive value for renal flares remains unknown. The PRE-FLARED study is a prospective multicenter biomarker study including 102 individuals with AAV in remission, aimed to predict renal relapse by quantifying urinary CD4+ T cell subsets using flow cytometry at baseline and monitoring clinical outcomes over a six-month follow-up. Among the participants, ten experienced renal relapses, two had non-renal flares, and 90 remained in stable remission. The median baseline urinary CD4+ T cell count was significantly higher in patients who relapsed compared to those in remission. Receiver operator characteristic (ROC) curve analysis of urinary CD4+ T cell counts showed an area under the curve (AUC) value of 0.88 for predicting renal flares, outperforming ANCA titers, hematuria, and proteinuria. Using a cut-off of 490 CD4+ T cells per 100 mL urine, the sensitivity and specificity in identifying patients with future renal flares were 60% and 97.8%, respectively. In a post-hoc analysis, combining urinary CD4+ T cell counts with PR3-ANCA levels suggested improved predictive performance in the PR3+ subgroup. Additionally, the number of urinary CD4+ T cells showed a limited correlation with a decline in glomerular filtration rate (GFR) and an increase in proteinuria over the follow-up period. The study concluded that urinary CD4+ T cell counts could identify AAV patients at a substantial risk of renal relapse within six months. Combining these counts with ANCA levels further improved the prediction of relapse. These findings have implications for personalized management strategies in patients with renal AAV.

Sections du résumé

BACKGROUND BACKGROUND
In ANCA-associated vasculitis (AAV) there is a lack of biomarkers for predicting renal relapse. Urinary T cells have been shown to differentiate active glomerulonephritis from remission in AAV, but their predictive value for renal flares remains unknown.
METHODS METHODS
The PRE-FLARED study is a prospective multicenter biomarker study including 102 individuals with AAV in remission, aimed to predict renal relapse by quantifying urinary CD4+ T cell subsets using flow cytometry at baseline and monitoring clinical outcomes over a six-month follow-up.
RESULTS RESULTS
Among the participants, ten experienced renal relapses, two had non-renal flares, and 90 remained in stable remission. The median baseline urinary CD4+ T cell count was significantly higher in patients who relapsed compared to those in remission. Receiver operator characteristic (ROC) curve analysis of urinary CD4+ T cell counts showed an area under the curve (AUC) value of 0.88 for predicting renal flares, outperforming ANCA titers, hematuria, and proteinuria. Using a cut-off of 490 CD4+ T cells per 100 mL urine, the sensitivity and specificity in identifying patients with future renal flares were 60% and 97.8%, respectively. In a post-hoc analysis, combining urinary CD4+ T cell counts with PR3-ANCA levels suggested improved predictive performance in the PR3+ subgroup. Additionally, the number of urinary CD4+ T cells showed a limited correlation with a decline in glomerular filtration rate (GFR) and an increase in proteinuria over the follow-up period.
CONCLUSIONS CONCLUSIONS
The study concluded that urinary CD4+ T cell counts could identify AAV patients at a substantial risk of renal relapse within six months. Combining these counts with ANCA levels further improved the prediction of relapse. These findings have implications for personalized management strategies in patients with renal AAV.

Identifiants

pubmed: 38231590
doi: 10.1681/ASN.0000000000000311
pii: 00001751-990000000-00240
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Berlin Institute of Health

Informations de copyright

Copyright © 2024 by the American Society of Nephrology.

Auteurs

Luka Prskalo (L)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Christopher M Skopnik (CM)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Nina Goerlich (N)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Paul Freund (P)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Leonie Wagner (L)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Emil Grothgar (E)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Pouneh Mirkheshti (P)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Jan Klocke (J)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Janis Sonnemann (J)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Diana Metzke (D)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Udo Schneider (U)

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Germany.

Falk Hiepe (F)

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Germany.

Kai-Uwe Eckardt (KU)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Alan D Salama (AD)

University College London Department of Renal Medicine, Royal Free Hospital, London, UK.

Markus Bieringer (M)

Department of Nephrology, Helios Klinikum Berlin-Buch, Berlin, Germany.

Adrian Schreiber (A)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Philipp Enghard (P)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Foundation, Berlin, Germany.

Classifications MeSH